Literature DB >> 2932587

Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells.

C Marth, G Böck, G Daxenbichler.   

Abstract

The synthetic retinoid 4-hydroxyphenylretinamide (HPR) showed antiproliferative effect on cultured human breast cancer cells, which were sensitive to retinoic acid (RA) too. Investigation of the cell cycle by flow cytophotometry showed a significant increase of cells in the S-phase of the cell cycle after 24 hours of RA treatment, whereas HPR did not show this effect. After 4-7 days of retinoid treatment, the percentage of resting cells increased. The influence on the cell cycle and the antiproliferative effect were more pronounced for RA than for HPR treatment in both cell lines investigated (ZR-75.1 and 734 B).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932587     DOI: 10.1093/jnci/75.5.871

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

Review 1.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins.

Authors:  Richard A Lytle; Zhihong Jiang; Xiao Zheng; Ryuji Higashikubo; Keith M Rich
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

3.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells.

Authors:  Y Liu; M O Lee; H G Wang; Y Li; Y Hashimoto; M Klaus; J C Reed; X Zhang
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  Inhibitory effects of selenium, vitamin A and butylated hydroxytoluene on in vitro growth of human tongue cancer cells.

Authors:  I Inoue; Y Yamamoto; T Takasaki; H Takahashi
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

5.  Fenretinide activates caspases and induces apoptosis in gliomas.

Authors:  V K Puduvalli; Y Saito; R Xu; G P Kouraklis; V A Levin; A P Kyritsis
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  Phase II trial of fenretinide in advanced renal carcinoma.

Authors:  Ulka Vaishampayan; Lance K Heilbrun; Ralph E Parchment; Vikash Jain; James Zwiebel; Ramesh R Boinpally; Patricia LoRusso; Maha Hussain
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

7.  Regulation of the expression of alkaline phosphatase in a human breast-cancer cell line.

Authors:  T C Chang; J K Wang; M W Hung; C H Chiao; L C Tsai; G G Chang
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

8.  Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Authors:  Bryan J Schneider; Francis P Worden; Shirish M Gadgeel; Ralph E Parchment; Collette M Hodges; James Zwiebel; Rodney L Dunn; Antoinette J Wozniak; Michael J Kraut; Gregory P Kalemkerian
Journal:  Invest New Drugs       Date:  2009-02-19       Impact factor: 3.850

9.  Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.

Authors:  H P Ciolino; T T Wang; N Sathyamoorthy
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

Authors:  R E Favoni; A de Cupis; S Bruno; D Yee; A Ferrera; P Pirani; A Costa; A Decensi
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.